The role of bisphosphonates for the treatment of bone disease in multiple myeloma

Leukemia and Lymphoma

Volumn 31, Issue 5-6, 1998, Pages 453-462

  Musto, Pellegrino ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Bisphosphonates; Bone pain; Clodronate; Etidronate; Hypercalcemia; Multiple myeloma; Osteolytic lesions; Pamidronate; Quality of life; Supportive therapy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID;

ARTICLE; BONE ATROPHY; BONE DISEASE; BONE PAIN; BONE TURNOVER; HUMAN; HYPERCALCEMIA; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; QUALITY OF LIFE;

EID: 0032449964     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809057605     Document Type: Article

References (80)

1. Mundy, G.R., and Bertolini, D.R. (1986) Bone destruction and hypercalcemia in multiple myeloma. Semin. Hematol., 13, 291-299.
2. Ascari, E., Merlini, G., and Riccardi, A. (1989) La malattia ossea mielomatosa. Proceedings of the XXXIV Congress of the Italian Society of Internal Medicine, 326-333.
3. Weinstein, R.S. (1992) Bone involvement in multiple myeloma. Am. J. Med., 93, 591-594.
4. Kyle, R.A. (1975) Multiple myeloma: review of 969 cases. Mayo Clin. Proc., 50, 29-40.
5. Wisloff, F., Eika, S., Hippe, E., Hjoerth, M., Holmberg, E., Kaasa, S., Palva, I., and Westin, J., for the Nordic Myeloma Study Group. (1996) Measurement of health-related quality of life in multiple myeloma. Br. J. Haematol., 92, 604-613.
6. Rosol, T.J., and Capen, C.C. (1994) Mechanisms of cancer-induced hypercalcemia. Lab. Invest., 67, 680-702.
7. Bataille, R., Manolagas, S.C., and Berenson, J.R. (1997) Pathogenesis and management of bone lesions in multiple myeloma. Hematol. Oncol. Clin. North Am.: Multiple myeloma, 11, 285-295.
8. Bataille, R., Delmas, P.D., Chappard, D., and Sany, J. (1990) Abnormal serum bone gla-protein levels in multiple myeloma: crucial role of bone formation and prognostic implications. Cancer, 66, 167-172.
9. Bataille, R., Chappard, D., Alexander, C., and Sany, J. (1986) Importance of quantitative histology of bone changes in monoclonal gammopathy. Br. J. Cancer, 53, 805-810.
10. Bataille, R., Chappard, D., Marcelli, C., Dessauw, P., Sany, J., Baldet, P., and Alexandre, C. (1991) The recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J. Clin. Invest., 88, 62-456.
11. Vinholes, J., Guo, C.Y., Purhoit, O.P., Eastell, R., and Coleman, R.E. (1997) Evaluation of new bone resorption in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancies. J. Clin. Oncol., 15, 131-138.
12. Mundy, G.R., Raisz, R.G., Cooper, R.A., Schechter, G.P., and Salmon, S.E. (1974) Evidence for the secretion of an osteoclast stimulating factor in multiple myeloma. N. Engl. J. Med., 291, 1041-1046.
13. Klein, B., and Bataille, R. (1992) Cytokine network in human multiple myeloma. Hematol. Oncol. Clin. North Am.: Multiple myeloma, 6, 273-284.
14. Manolagas, S.C., and Jilka, R. (1995) Bone marrow, cytokines and bone remodelling. N. Engl. J. Med., 332, 305-311.
15. Bertolini, D.R., Nedwin, G.E., Bringman, T.S., Smith, D.D. and Mundy, G. (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by tumor necrosis factor. Nature, 319, 516-518.
16. Kawano, M., Yamamoto, Y., and Iwato, K. (1989) Interleukin-1 beta rather than lymphotoxin as a major bone resorbing activity in multiple myeloma. Blood, 73, 1646-1649.
17. Kurihara, N., Bertolini, D., Suda, T., Akiyama, Y., and Roodman, G.D. (1990) IL-6 stimulates osteoclast-like multi-nucleated cell formation in long term human marrow cultures by inducing IL-1 release. J. Immunol., 144, 4226-4230.
18. Mundy, G.R. (1992) Cytokines and local factors which affect osteoclast function. Int. J. Cell Clon., 10, 215-222.
19. Stashenko, P., Dewhirst, F.E., and Peros, W.J., (1987) Synergistic interactions between interleukin-1, tumor necrosis factor and lymphotoxin in bone resorption.. J. Immunol., 138, 1464-1470.
20. San Miguel J.F. (1996) Supportive therapy for complications in multiple myeloma. Education Programme of the 2nd European Hematology Association Congress, Paris, 29 May-1 June, 1996, 12-16.
21. Montillo, M., Tedeschi, A., Capelli, D., and Leoni, P. (1996) Lesioni ossee ed ipercalcemia. In: Morra, E., ed, Il mieloma multiplo: attualita' di biologia e terapia. Eliotecnica Grafica, Cornaredo, 89-102.
22. Rodriguez, L.H., Finkelstein, J.B., Schullenberger, C.C., and Alexanian, R. (1972) Bone healing in multiple myeloma with melphalan chemotherapy. Ann. Int. Med., 76, 551-556.
23. Kyle, R.A., Jowsey, J., Kelly, P.J., and Taves, D.R. (1975). Multiple myeloma bone disease: the comparative effect of sodium fluoride and calcium carbonate or placebo. N. Engl. J. Med., 293, 1334-1338.
24. Cohen, H.J., Silberman, H.R., Trnyos, K., Bartolucci, A.A., and the Southeastern Cancer Study Group (1984) Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. Blood, 63, 639-648.
25. Warrel, R.P., Murphy, W.K., Schulman, P., O'Dwyer, P., and Heller, G. (1991) Gallium nitrate for the treatment of cancer related hypercalcemia: a randomized double-blind comparison to etidronate. J. Clin. Oncol., 9, 1467-1475.
26. Harley, J.B., Schilling, A., Glidewell, O., for the Acute Leukemia Study Group B. and Eastern Cooperative Oncology Group. (1972) Ineffectiveness of fluoride therapy in multiple myeloma. N. Engl. J. Med., 286, 1283-1288.
27. Fleisch H. (1991) Bisphosphonates: pharmacology and use in treatment of tumor induced hypercalcaemia and metastatic bone disease. Drugs, 42, 919-944.
28. Lin, J.H. (1996) Bisphosphonates: a review of their pharmacokinetic properties. Bone, 18, 75-85.
29. Rodan, G.A., and Heisch, H.A. (1996) Bisphosphonates: mechanisms of action. J. Clin. Invest. 97, 2692-2696.
30. Jantunen, E. and Laakso, M. (1996) Bisphosphonates in multiple myeloma: current status, future perspectives. Br. J. Haematol., 93, 501-506.
31. Savage, A.D., Belson, D.J., Vescio, R. A., Lichtenstein, A.K., and Berenson, J.R. (1996) Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients. Blood, 88, 105a (abstract).
32. Purohit O.P., Radstone, C.R., Owen, J., Anthony, C., and Coleman, R.E. (1994) High dose intravenous pamidronate for metastatic bone pain. Br. J. Cancer, 70, 554-558.
33. Bataille R. (1996) Management of myeloma with bisphosphonates. N. Engl. J. Med., 334, 529-530.
34. Paterson, A.D., Kanis, J.A., and Cameron, E.C. (1983) The use of dichloromethylene diphosphonate for the management of hypercalcemia in multiple myeloma. Br. J. Haematol., 54, 121-132.
35. Nussbaum, S.R., Younger, J., and Vandepol, C.J. (1993) Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30, 60 and 90 mg dosages. Am. J. Med., 95, 297-304.
36. Purhoit, O.P., Radstone, C.R., Anthony, C., Kanis, J.A., and Coleman, R.E. (1995) A randomized double-blind comparison of intravenous pamidronate and clodronate in the hypercalcemia of malignancy. Br. J. Cancer, 72, 1289-93.
37. Gucalp, R., Ritch, P., Weimik P.H., Sarma, P.R., Keller, A., Richman, S.P., Tauer, K., Neidhart, J., Mallette, L.E., Siegel, R., and Vanderpol, C.J. (1992) Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J. Clin. Oncol., 10, 134-142.
38. O'Rourke, N.P., McCloskey, E.V., Vasikaran, S., Eyres, K., Fern, D., and Kanis, J.A. (1993) Effective treatment of malignant hypercalcemia with a single intravenous infusion of clodronate. Br. J. Cancer, 67, 560-563.
39. Ralston, S.H., Gallagher, S.J., Patel, U., Dryburgh, F.J., Fraser, W.D., Cowan, R.A., and Boyle, I.T. (1989). Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet, 2, 1180-1182.
40. Singer, F.R. (1990) Role of the bisphosphonate etidronate in the therapy of cancer-related hypercalcemia. Semin. Oncol., 17, 24-38.
41. Thiebaud, D., Jaeger, P., Jacquet, A.F., and Burckhardt, P. (1988) Dose response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP (APD). J. Clin. Oncol., 6, 762-768.
42. Jacobs, T.P., Siris, E.S., Bilezikian, J.P., Baguiran, D.C., Shane, E., and Canfield, R.E. (1981) Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate. Ann. Int. Med., 94, 312-316.
43. Percival, R.C., Paterson, A.D., and Yates, A.J.P. (1985) Treatment of malignant hypercalcemia with clodronate. Br. J. Cancer, 51, 665-669.
44. Siris, E.S., Sherman, W.H., Baquiran, D.C., Schlatterer, J.P., Osserman, E.F., Canfield, R.E. (1980) Effects of dichloromethylene diphosphonate on skeleton mobilization of calcium in multiple myeloma. N. Engl. J. Med., 302, 310-315.
45. Urwin, J.H., Yates, A.J.P., Gray, R.E.S., Hamdy, N.A.T., McCloskey E.V., Preston, F.E., Greaves, M., Neil, F.E., and Kanis, J.A. (1987) Treatment of hypercalcemia of malignancy with intravenous clodronate. Bone (8 (suppl. 1), S43-S51.
46. Body, J.J., and Dumon, J.C. (1994) Treatment of tumor induced hypercalcemia with the bisphosphonate pamidronate. Ann. Oncol., 359-363.
47. Jung, A. (1982) Comparison of two parental diphosphonates in hypercalcemia of malignancies. Am. J. Med., 72, 221-226.
48. Belch, A.R., Bergsagel, D.E., Wilson, K., O'Reilly, S., Wilson, J., Sutton, D., Pater, J., Johnston, D., and Zee, B. (1991) Effect of daily etidronate on the osteolysis in multiple myeloma. J. Clin. Oncol., 9, 1397-1402.
49. Daragon, A., Humez, C., Michot, C., Le Loet, X., Grosbols, B., Pouyol, F., Euller-Ziegler, L., Azais, I., Bernard, J.F., Menard, J.F., and Monconduit, M., for the Groupe d'Etudes et de Recherches sur le Myelome (GERM) (1993) Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Eur. J. Med., 2, 449-452.
50. Delmas, P.D., Charbon, S., Chapuy, M.C., Vignon, E., Briancon, D., Edouard, C., and Meunier, P.J. (1982) Long term effects of dichloromethylene dis-phosphonate (C12-MDP) on skeletal lesions in multiple myeloma. Metab. Bone. Dis. Relat. Res., 4, 163-168.
51. Merlini, G., Parrinello, G.A., Piccinini, L., Crema, F., Fiorentini, M.L., Riccardi, A., Pavesi, F., Novazzi, F., Silingardi, V., Ascari, E. (1990) Long term effects of parenteral dichloromethylene biphosphonate (C12-MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol. Oncol., 8, 23-30.
52. Lahtinen, R., Laakso, M., Palva, I., Virkkumen, P., and Elomaa, P., for the Finnish Leukaemia Group. (1992) Randomised, placebo-controlled multicentrc trial of clodronate in multiple myeloma. Lancet, 340, 1049-1052.
53. Laakso, M., Lahtinen, R., Virkkumen, P., and Elomaa, I. (1994) Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Br. J. Haematol., 87, 725-729.
54. Laakso, M, for the Finnish Leukaemia Group. (1993) Clodronate for multiple myeloma. Lancet, 341, 175-176.
55. Clemens, M.R., Fessele, K., and Heim, M.E. (1993) Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications. Ann. Hematol., 66, 141-146.
56. Heim, M.E., Clemens, M.R., Queisser, W., Pecherstorfer, M., Boewer, C., Herold, M., Franke, A., Hermann, Z., Looser, R., Edler, L. (1995) Prospective randomized trial of dichloromethylene bisphosphonate (clodronate) in patients with multiple myeloma requiring treatment. A multicenter study. Onkologie, 18, 439-448.
57. McCloskey, E.V., MacLennan, I.C.M., Drayson, M., Chapman, C., Dunn, J., and Kanis, J.A. (1996) Effects of clodronate on morbidity and mortality in myelomatosis. Ann. Oncol., 7, (suppl. 5), 4120 (abstract).
58. Man, Z., Otero, A.B., Rendo, P., Barazzutti, L., and Sanchez Avalos, J.C. (1990) Use of pamidronate for multiple myeloma osteolytic lesions. Lancet, 335, 663.
59. Thiebaud, D., Leyvraz, S., von Fliedner, V., Perey, L., Cornu, P., Thiebaud, S., and Burckardt, P. (1991) Treatment of bone metastases from breast cancer and myeloma with pamidronate. Eur. J. Cancer, 27, 37-41.
60. Thurlimann, B., Morant, R., Jungi, W.F., and Radziwill, A. (1994) Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support. Care Cancer, 2, 61-65.
61. Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M.J., Blacklock, H.A., Bell, R., Simeone, J., Reitsma, D.J., Heffernan, M., Seaman, J., and Knight, D., for the Myeloma Aredia Study Group (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N. Engl. J. Med., 334, 488-493.
62. Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., Blacklock, H., Bell, R., Simeone, G.F., Reitsma, D.J., Heffernan, M., Seaman, J., and Knight, D. (1998) Long term pamidronate treatment of advanced multiple myeloma reduces skeletal events. J. Clin. Oncol., 16, 593-602.
63. Berenson, J.R. (1997) Bisphosphonate therapy of myeloma. VI International Worshop on Multiple Myeloma, Syllabus, Boston, June 14-18, 1997.
64. Anderson, K., Kyle, R.A., and Berenson, J. (1997) Multiple myeloma. Education Program, 39th Annual Meeting American Society of Hematology. S. Diego, December 5-9, 1997, 177-188.
65. Musto, P., Falcone, A., Bodenizza, C., Vigliotti, M.L., Sanpaolo, G., De Renzo, A., Rotoli, B., and Carotenuto, M. (1996) Pamidronate has significant effects on bone disease of patients with advanced multiple myeloma. Multiple Myeloma: Advances in Biology and Treatment., Wien, September 13-14, 1996, 70 (abstract).
66. Attal, M., Harousseau, J.L., Stoppa, A.M., Sotto, J.J., Fuzibet, J.G., Rossi, J.F., Casassus, P., Maissoneuve, H., Facon, T., Ifrah, N., Payen, C., and Bataille, R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med., 335, 91-97.
67. Barlogie, B., Jagannath, S., Vesole, D., Tricot, G., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Jacobson, J., and Crowley, J., (1997) Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood, 89, 789-793.
68. Boccadoro, M., Palumbo, A., Argentino, C., Dominietto, A., Frieri, R., Avvisati, G., Comotti, B., Lauta, V.M., Liberati, M., Marmont, F., Musto, P., Tribalto, M., and Pileri, A. (1997) Conventional induction treatments do not influence overall survival in multiple myeloma. Br. J. Haematol., 96, 333-337.
69. Morton, A. (1995) The role of bisphosphonates in patients with bony metastases. Cancer J., 8, 231-233.
70. Fitton, A., and McTavish, D. (1991) Pamidronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs, 41, 289-318.
71. Plosker, G.L., and Goa, K.L. (1994) Clodronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs, 47, 945-982.
72. De Groen, P.C., Lubbe, D.F., Hirsch, L.J., Daifotis, A., Stephenson, W., Freedholm, D., Pryor-Tillotson, S., Seleznick, M.J., Pinkas, H., and Wang, K.K. (1996) Esophagitis associated with the use of alendronate. N. Engl. J. Med., 335, 1016-1021.
73. Tyrrell, C.J., Collisons, M, Madsen, E.I., Ford, J.M., and Coleman, T. (1994) Intravenous pamidronate: infusion rate and safety. Ann. Oncol., 5, 37-40.
74. Savage, A.D., Belson, D.J., and Vescio, R.A. (1998) Pamidronate reduces IL-6 production by bone marrow dendritic cell cultures in a dose and drug potency dependent manner. Submitted for publication.
75. Shipman, C.M., Rogers, M.J., Apperley, J.F., Russel, G.G., and Croucher, P.I. (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br. J. Haematol., 98, 665-672.
76. Aparicio, A., Gardner, A., and Tu, Y. (1998) In vitro cytoreductive effects of multiple myeloma cells induced by bisphosphonates. Leukemia (in press).
77. Gerz, B.J., Holland, S.D., Kline, W.F., Matuszewsky, B.K., and Porras, A.G. (1993) Clinical pharmacology of alendronate sodium. Osteop. Intern., 3 (suppl. 3), S13-S16.
78. Reginster, J.Y.L. (1992) Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. Bone, 13, 351-354.
79. Roux, C., Ravaud, P., Cohen-Solal, M., De Vernejoul, M.C., Guillemant, S., Cherrau, B., Delmas, P., Dougados, M, and Amor, B. (1994) Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone, 15, 41-49.
80. Green, J.R., Muller, K., Jaeggi, K.A. (1994) Preclinical pharmacology of CGP 42446, a new potent, heterocyclic bisphosphonate compound. J. Bone Miner., 9, 745-750.